1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in a longer median overall survival versus comparator EGFR-TKIs with similar safety profiles.
2. Benefits appeared to extend across most predefined subgroups including sex, age, and smoking history, although there was...